PMC:7102591 / 2449-3697 JSONTXT

{"project":"LitCovid-PubTator","denotations":[{"id":"88","span":{"begin":992,"end":1005},"obj":"Gene"},{"id":"89","span":{"begin":1007,"end":1011},"obj":"Gene"},{"id":"90","span":{"begin":120,"end":128},"obj":"Species"},{"id":"91","span":{"begin":319,"end":327},"obj":"Species"},{"id":"92","span":{"begin":811,"end":822},"obj":"Chemical"},{"id":"93","span":{"begin":827,"end":845},"obj":"Chemical"},{"id":"94","span":{"begin":81,"end":89},"obj":"Disease"},{"id":"95","span":{"begin":112,"end":119},"obj":"Disease"},{"id":"96","span":{"begin":630,"end":650},"obj":"Disease"},{"id":"97","span":{"begin":726,"end":746},"obj":"Disease"},{"id":"98","span":{"begin":748,"end":750},"obj":"Disease"},{"id":"99","span":{"begin":801,"end":809},"obj":"Disease"},{"id":"100","span":{"begin":943,"end":961},"obj":"Disease"},{"id":"101","span":{"begin":1143,"end":1154},"obj":"Disease"},{"id":"102","span":{"begin":1174,"end":1178},"obj":"Disease"},{"id":"103","span":{"begin":1224,"end":1242},"obj":"Disease"}],"attributes":[{"id":"A88","pred":"tao:has_database_id","subj":"88","obj":"Gene:3569"},{"id":"A89","pred":"tao:has_database_id","subj":"89","obj":"Gene:3569"},{"id":"A90","pred":"tao:has_database_id","subj":"90","obj":"Tax:9606"},{"id":"A91","pred":"tao:has_database_id","subj":"91","obj":"Tax:9606"},{"id":"A92","pred":"tao:has_database_id","subj":"92","obj":"MESH:D002738"},{"id":"A93","pred":"tao:has_database_id","subj":"93","obj":"MESH:D006886"},{"id":"A94","pred":"tao:has_database_id","subj":"94","obj":"MESH:C000657245"},{"id":"A95","pred":"tao:has_database_id","subj":"95","obj":"MESH:D005600"},{"id":"A96","pred":"tao:has_database_id","subj":"96","obj":"MESH:C000657245"},{"id":"A97","pred":"tao:has_database_id","subj":"97","obj":"MESH:D001172"},{"id":"A98","pred":"tao:has_database_id","subj":"98","obj":"MESH:D001172"},{"id":"A99","pred":"tao:has_database_id","subj":"99","obj":"MESH:C000657245"},{"id":"A100","pred":"tao:has_database_id","subj":"100","obj":"MESH:C000657245"},{"id":"A101","pred":"tao:has_database_id","subj":"101","obj":"MESH:D008171"},{"id":"A102","pred":"tao:has_database_id","subj":"102","obj":"MESH:D012128"},{"id":"A103","pred":"tao:has_database_id","subj":"103","obj":"MESH:C000657245"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"In this context of growing health emergency, clarifying the relationship between COVID-19 and the population of fragile patients suffering from immune-rheumatological diseases is absolutely crucial. On the one hand, the rapid and uncontrolled spread of the epidemic can clearly generate even more concerns in rheumatic patients, which are intrinsically characterized by an increased infectious risk due to the disease itself and to the iatrogenic effect of immunosuppressive agents such as corticosteroids and synthetic or biological disease-modifying drugs [9]. On the other hand, the growing knowledge about the pathogenesis of SARS-CoV-2 infection is leading to the introduction of drugs commonly used for the treatment of rheumatoid arthritis (RA) even for the management of more complex cases of COVID-19. Chloroquine and hydroxychloroquine have now been permanently included, alongside antiviral drugs, in protocols for the treatment of COVID-19 pneumonia [10]. In addition, the use of interleukin 6 (IL-6) blockers seems to be very promising for the management of the massive cytokine storm associated to the development of the typical lung damage and the consequent ARDS occurring in the most aggressive patterns of SARS-CoV infection [11]."}

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T4","span":{"begin":210,"end":214},"obj":"Body_part"},{"id":"T5","span":{"begin":576,"end":580},"obj":"Body_part"},{"id":"T6","span":{"begin":992,"end":1005},"obj":"Body_part"},{"id":"T7","span":{"begin":992,"end":1003},"obj":"Body_part"},{"id":"T8","span":{"begin":1083,"end":1091},"obj":"Body_part"},{"id":"T9","span":{"begin":1143,"end":1147},"obj":"Body_part"}],"attributes":[{"id":"A4","pred":"fma_id","subj":"T4","obj":"http://purl.org/sig/ont/fma/fma9712"},{"id":"A5","pred":"fma_id","subj":"T5","obj":"http://purl.org/sig/ont/fma/fma9712"},{"id":"A6","pred":"fma_id","subj":"T6","obj":"http://purl.org/sig/ont/fma/fma264829"},{"id":"A7","pred":"fma_id","subj":"T7","obj":"http://purl.org/sig/ont/fma/fma86578"},{"id":"A8","pred":"fma_id","subj":"T8","obj":"http://purl.org/sig/ont/fma/fma84050"},{"id":"A9","pred":"fma_id","subj":"T9","obj":"http://purl.org/sig/ont/fma/fma7195"}],"text":"In this context of growing health emergency, clarifying the relationship between COVID-19 and the population of fragile patients suffering from immune-rheumatological diseases is absolutely crucial. On the one hand, the rapid and uncontrolled spread of the epidemic can clearly generate even more concerns in rheumatic patients, which are intrinsically characterized by an increased infectious risk due to the disease itself and to the iatrogenic effect of immunosuppressive agents such as corticosteroids and synthetic or biological disease-modifying drugs [9]. On the other hand, the growing knowledge about the pathogenesis of SARS-CoV-2 infection is leading to the introduction of drugs commonly used for the treatment of rheumatoid arthritis (RA) even for the management of more complex cases of COVID-19. Chloroquine and hydroxychloroquine have now been permanently included, alongside antiviral drugs, in protocols for the treatment of COVID-19 pneumonia [10]. In addition, the use of interleukin 6 (IL-6) blockers seems to be very promising for the management of the massive cytokine storm associated to the development of the typical lung damage and the consequent ARDS occurring in the most aggressive patterns of SARS-CoV infection [11]."}

{"project":"LitCovid-PD-UBERON","denotations":[{"id":"T2","span":{"begin":210,"end":214},"obj":"Body_part"},{"id":"T3","span":{"begin":576,"end":580},"obj":"Body_part"},{"id":"T4","span":{"begin":1143,"end":1147},"obj":"Body_part"}],"attributes":[{"id":"A2","pred":"uberon_id","subj":"T2","obj":"http://purl.obolibrary.org/obo/UBERON_0002398"},{"id":"A3","pred":"uberon_id","subj":"T3","obj":"http://purl.obolibrary.org/obo/UBERON_0002398"},{"id":"A4","pred":"uberon_id","subj":"T4","obj":"http://purl.obolibrary.org/obo/UBERON_0002048"}],"text":"In this context of growing health emergency, clarifying the relationship between COVID-19 and the population of fragile patients suffering from immune-rheumatological diseases is absolutely crucial. On the one hand, the rapid and uncontrolled spread of the epidemic can clearly generate even more concerns in rheumatic patients, which are intrinsically characterized by an increased infectious risk due to the disease itself and to the iatrogenic effect of immunosuppressive agents such as corticosteroids and synthetic or biological disease-modifying drugs [9]. On the other hand, the growing knowledge about the pathogenesis of SARS-CoV-2 infection is leading to the introduction of drugs commonly used for the treatment of rheumatoid arthritis (RA) even for the management of more complex cases of COVID-19. Chloroquine and hydroxychloroquine have now been permanently included, alongside antiviral drugs, in protocols for the treatment of COVID-19 pneumonia [10]. In addition, the use of interleukin 6 (IL-6) blockers seems to be very promising for the management of the massive cytokine storm associated to the development of the typical lung damage and the consequent ARDS occurring in the most aggressive patterns of SARS-CoV infection [11]."}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T33","span":{"begin":81,"end":89},"obj":"Disease"},{"id":"T34","span":{"begin":383,"end":393},"obj":"Disease"},{"id":"T35","span":{"begin":630,"end":638},"obj":"Disease"},{"id":"T36","span":{"begin":641,"end":650},"obj":"Disease"},{"id":"T37","span":{"begin":726,"end":746},"obj":"Disease"},{"id":"T38","span":{"begin":737,"end":746},"obj":"Disease"},{"id":"T39","span":{"begin":748,"end":750},"obj":"Disease"},{"id":"T41","span":{"begin":801,"end":809},"obj":"Disease"},{"id":"T42","span":{"begin":943,"end":951},"obj":"Disease"},{"id":"T43","span":{"begin":952,"end":961},"obj":"Disease"},{"id":"T44","span":{"begin":1174,"end":1178},"obj":"Disease"},{"id":"T45","span":{"begin":1224,"end":1242},"obj":"Disease"},{"id":"T46","span":{"begin":1233,"end":1242},"obj":"Disease"}],"attributes":[{"id":"A33","pred":"mondo_id","subj":"T33","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A34","pred":"mondo_id","subj":"T34","obj":"http://purl.obolibrary.org/obo/MONDO_0005550"},{"id":"A35","pred":"mondo_id","subj":"T35","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A36","pred":"mondo_id","subj":"T36","obj":"http://purl.obolibrary.org/obo/MONDO_0005550"},{"id":"A37","pred":"mondo_id","subj":"T37","obj":"http://purl.obolibrary.org/obo/MONDO_0008383"},{"id":"A38","pred":"mondo_id","subj":"T38","obj":"http://purl.obolibrary.org/obo/MONDO_0005578"},{"id":"A39","pred":"mondo_id","subj":"T39","obj":"http://purl.obolibrary.org/obo/MONDO_0005272"},{"id":"A40","pred":"mondo_id","subj":"T39","obj":"http://purl.obolibrary.org/obo/MONDO_0008383"},{"id":"A41","pred":"mondo_id","subj":"T41","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A42","pred":"mondo_id","subj":"T42","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A43","pred":"mondo_id","subj":"T43","obj":"http://purl.obolibrary.org/obo/MONDO_0005249"},{"id":"A44","pred":"mondo_id","subj":"T44","obj":"http://purl.obolibrary.org/obo/MONDO_0006502"},{"id":"A45","pred":"mondo_id","subj":"T45","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A46","pred":"mondo_id","subj":"T46","obj":"http://purl.obolibrary.org/obo/MONDO_0005550"}],"text":"In this context of growing health emergency, clarifying the relationship between COVID-19 and the population of fragile patients suffering from immune-rheumatological diseases is absolutely crucial. On the one hand, the rapid and uncontrolled spread of the epidemic can clearly generate even more concerns in rheumatic patients, which are intrinsically characterized by an increased infectious risk due to the disease itself and to the iatrogenic effect of immunosuppressive agents such as corticosteroids and synthetic or biological disease-modifying drugs [9]. On the other hand, the growing knowledge about the pathogenesis of SARS-CoV-2 infection is leading to the introduction of drugs commonly used for the treatment of rheumatoid arthritis (RA) even for the management of more complex cases of COVID-19. Chloroquine and hydroxychloroquine have now been permanently included, alongside antiviral drugs, in protocols for the treatment of COVID-19 pneumonia [10]. In addition, the use of interleukin 6 (IL-6) blockers seems to be very promising for the management of the massive cytokine storm associated to the development of the typical lung damage and the consequent ARDS occurring in the most aggressive patterns of SARS-CoV infection [11]."}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T15","span":{"begin":992,"end":1005},"obj":"http://purl.obolibrary.org/obo/PR_000001393"},{"id":"T16","span":{"begin":1143,"end":1147},"obj":"http://purl.obolibrary.org/obo/UBERON_0002048"},{"id":"T17","span":{"begin":1143,"end":1147},"obj":"http://www.ebi.ac.uk/efo/EFO_0000934"},{"id":"T18","span":{"begin":1244,"end":1246},"obj":"http://purl.obolibrary.org/obo/CLO_0053733"}],"text":"In this context of growing health emergency, clarifying the relationship between COVID-19 and the population of fragile patients suffering from immune-rheumatological diseases is absolutely crucial. On the one hand, the rapid and uncontrolled spread of the epidemic can clearly generate even more concerns in rheumatic patients, which are intrinsically characterized by an increased infectious risk due to the disease itself and to the iatrogenic effect of immunosuppressive agents such as corticosteroids and synthetic or biological disease-modifying drugs [9]. On the other hand, the growing knowledge about the pathogenesis of SARS-CoV-2 infection is leading to the introduction of drugs commonly used for the treatment of rheumatoid arthritis (RA) even for the management of more complex cases of COVID-19. Chloroquine and hydroxychloroquine have now been permanently included, alongside antiviral drugs, in protocols for the treatment of COVID-19 pneumonia [10]. In addition, the use of interleukin 6 (IL-6) blockers seems to be very promising for the management of the massive cytokine storm associated to the development of the typical lung damage and the consequent ARDS occurring in the most aggressive patterns of SARS-CoV infection [11]."}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T10","span":{"begin":457,"end":481},"obj":"Chemical"},{"id":"T11","span":{"begin":490,"end":505},"obj":"Chemical"},{"id":"T12","span":{"begin":552,"end":557},"obj":"Chemical"},{"id":"T13","span":{"begin":685,"end":690},"obj":"Chemical"},{"id":"T14","span":{"begin":748,"end":750},"obj":"Chemical"},{"id":"T15","span":{"begin":811,"end":822},"obj":"Chemical"},{"id":"T16","span":{"begin":827,"end":845},"obj":"Chemical"},{"id":"T17","span":{"begin":892,"end":907},"obj":"Chemical"},{"id":"T18","span":{"begin":892,"end":901},"obj":"Chemical"},{"id":"T19","span":{"begin":902,"end":907},"obj":"Chemical"},{"id":"T20","span":{"begin":1007,"end":1009},"obj":"Chemical"}],"attributes":[{"id":"A10","pred":"chebi_id","subj":"T10","obj":"http://purl.obolibrary.org/obo/CHEBI_35705"},{"id":"A11","pred":"chebi_id","subj":"T11","obj":"http://purl.obolibrary.org/obo/CHEBI_50858"},{"id":"A12","pred":"chebi_id","subj":"T12","obj":"http://purl.obolibrary.org/obo/CHEBI_23888"},{"id":"A13","pred":"chebi_id","subj":"T13","obj":"http://purl.obolibrary.org/obo/CHEBI_23888"},{"id":"A14","pred":"chebi_id","subj":"T14","obj":"http://purl.obolibrary.org/obo/CHEBI_73810"},{"id":"A15","pred":"chebi_id","subj":"T15","obj":"http://purl.obolibrary.org/obo/CHEBI_3638"},{"id":"A16","pred":"chebi_id","subj":"T16","obj":"http://purl.obolibrary.org/obo/CHEBI_5801"},{"id":"A17","pred":"chebi_id","subj":"T17","obj":"http://purl.obolibrary.org/obo/CHEBI_36044"},{"id":"A18","pred":"chebi_id","subj":"T18","obj":"http://purl.obolibrary.org/obo/CHEBI_22587"},{"id":"A19","pred":"chebi_id","subj":"T19","obj":"http://purl.obolibrary.org/obo/CHEBI_23888"},{"id":"A20","pred":"chebi_id","subj":"T20","obj":"http://purl.obolibrary.org/obo/CHEBI_63895"},{"id":"A21","pred":"chebi_id","subj":"T20","obj":"http://purl.obolibrary.org/obo/CHEBI_74072"}],"text":"In this context of growing health emergency, clarifying the relationship between COVID-19 and the population of fragile patients suffering from immune-rheumatological diseases is absolutely crucial. On the one hand, the rapid and uncontrolled spread of the epidemic can clearly generate even more concerns in rheumatic patients, which are intrinsically characterized by an increased infectious risk due to the disease itself and to the iatrogenic effect of immunosuppressive agents such as corticosteroids and synthetic or biological disease-modifying drugs [9]. On the other hand, the growing knowledge about the pathogenesis of SARS-CoV-2 infection is leading to the introduction of drugs commonly used for the treatment of rheumatoid arthritis (RA) even for the management of more complex cases of COVID-19. Chloroquine and hydroxychloroquine have now been permanently included, alongside antiviral drugs, in protocols for the treatment of COVID-19 pneumonia [10]. In addition, the use of interleukin 6 (IL-6) blockers seems to be very promising for the management of the massive cytokine storm associated to the development of the typical lung damage and the consequent ARDS occurring in the most aggressive patterns of SARS-CoV infection [11]."}

{"project":"LitCovid-PD-GO-BP","denotations":[{"id":"T1","span":{"begin":614,"end":626},"obj":"http://purl.obolibrary.org/obo/GO_0009405"}],"text":"In this context of growing health emergency, clarifying the relationship between COVID-19 and the population of fragile patients suffering from immune-rheumatological diseases is absolutely crucial. On the one hand, the rapid and uncontrolled spread of the epidemic can clearly generate even more concerns in rheumatic patients, which are intrinsically characterized by an increased infectious risk due to the disease itself and to the iatrogenic effect of immunosuppressive agents such as corticosteroids and synthetic or biological disease-modifying drugs [9]. On the other hand, the growing knowledge about the pathogenesis of SARS-CoV-2 infection is leading to the introduction of drugs commonly used for the treatment of rheumatoid arthritis (RA) even for the management of more complex cases of COVID-19. Chloroquine and hydroxychloroquine have now been permanently included, alongside antiviral drugs, in protocols for the treatment of COVID-19 pneumonia [10]. In addition, the use of interleukin 6 (IL-6) blockers seems to be very promising for the management of the massive cytokine storm associated to the development of the typical lung damage and the consequent ARDS occurring in the most aggressive patterns of SARS-CoV infection [11]."}

{"project":"LitCovid-sentences","denotations":[{"id":"T16","span":{"begin":0,"end":198},"obj":"Sentence"},{"id":"T17","span":{"begin":199,"end":562},"obj":"Sentence"},{"id":"T18","span":{"begin":563,"end":810},"obj":"Sentence"},{"id":"T19","span":{"begin":811,"end":967},"obj":"Sentence"},{"id":"T20","span":{"begin":968,"end":1248},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"In this context of growing health emergency, clarifying the relationship between COVID-19 and the population of fragile patients suffering from immune-rheumatological diseases is absolutely crucial. On the one hand, the rapid and uncontrolled spread of the epidemic can clearly generate even more concerns in rheumatic patients, which are intrinsically characterized by an increased infectious risk due to the disease itself and to the iatrogenic effect of immunosuppressive agents such as corticosteroids and synthetic or biological disease-modifying drugs [9]. On the other hand, the growing knowledge about the pathogenesis of SARS-CoV-2 infection is leading to the introduction of drugs commonly used for the treatment of rheumatoid arthritis (RA) even for the management of more complex cases of COVID-19. Chloroquine and hydroxychloroquine have now been permanently included, alongside antiviral drugs, in protocols for the treatment of COVID-19 pneumonia [10]. In addition, the use of interleukin 6 (IL-6) blockers seems to be very promising for the management of the massive cytokine storm associated to the development of the typical lung damage and the consequent ARDS occurring in the most aggressive patterns of SARS-CoV infection [11]."}

{"project":"LitCovid-PD-HP","denotations":[{"id":"T15","span":{"begin":726,"end":746},"obj":"Phenotype"},{"id":"T16","span":{"begin":748,"end":750},"obj":"Phenotype"},{"id":"T17","span":{"begin":952,"end":961},"obj":"Phenotype"},{"id":"T18","span":{"begin":1083,"end":1097},"obj":"Phenotype"}],"attributes":[{"id":"A15","pred":"hp_id","subj":"T15","obj":"http://purl.obolibrary.org/obo/HP_0001370"},{"id":"A16","pred":"hp_id","subj":"T16","obj":"http://purl.obolibrary.org/obo/HP_0001370"},{"id":"A17","pred":"hp_id","subj":"T17","obj":"http://purl.obolibrary.org/obo/HP_0002090"},{"id":"A18","pred":"hp_id","subj":"T18","obj":"http://purl.obolibrary.org/obo/HP_0033041"}],"text":"In this context of growing health emergency, clarifying the relationship between COVID-19 and the population of fragile patients suffering from immune-rheumatological diseases is absolutely crucial. On the one hand, the rapid and uncontrolled spread of the epidemic can clearly generate even more concerns in rheumatic patients, which are intrinsically characterized by an increased infectious risk due to the disease itself and to the iatrogenic effect of immunosuppressive agents such as corticosteroids and synthetic or biological disease-modifying drugs [9]. On the other hand, the growing knowledge about the pathogenesis of SARS-CoV-2 infection is leading to the introduction of drugs commonly used for the treatment of rheumatoid arthritis (RA) even for the management of more complex cases of COVID-19. Chloroquine and hydroxychloroquine have now been permanently included, alongside antiviral drugs, in protocols for the treatment of COVID-19 pneumonia [10]. In addition, the use of interleukin 6 (IL-6) blockers seems to be very promising for the management of the massive cytokine storm associated to the development of the typical lung damage and the consequent ARDS occurring in the most aggressive patterns of SARS-CoV infection [11]."}

{"project":"2_test","denotations":[{"id":"32205186-25172238-4826867","span":{"begin":559,"end":560},"obj":"25172238"}],"text":"In this context of growing health emergency, clarifying the relationship between COVID-19 and the population of fragile patients suffering from immune-rheumatological diseases is absolutely crucial. On the one hand, the rapid and uncontrolled spread of the epidemic can clearly generate even more concerns in rheumatic patients, which are intrinsically characterized by an increased infectious risk due to the disease itself and to the iatrogenic effect of immunosuppressive agents such as corticosteroids and synthetic or biological disease-modifying drugs [9]. On the other hand, the growing knowledge about the pathogenesis of SARS-CoV-2 infection is leading to the introduction of drugs commonly used for the treatment of rheumatoid arthritis (RA) even for the management of more complex cases of COVID-19. Chloroquine and hydroxychloroquine have now been permanently included, alongside antiviral drugs, in protocols for the treatment of COVID-19 pneumonia [10]. In addition, the use of interleukin 6 (IL-6) blockers seems to be very promising for the management of the massive cytokine storm associated to the development of the typical lung damage and the consequent ARDS occurring in the most aggressive patterns of SARS-CoV infection [11]."}